Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C

← catalyst calendar

NCT04166058 · results posted

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →. With Ironwood Pharmaceuticals, Inc..

Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
381actual
Sites
72
Countries
Canada, Israel, Netherlands +1

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2019-11-19actualWhen the study began enrolling
Primary completion2025-06-05actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-06-05actualThe whole study's end, after follow-up
First posted2019-11-18actualWhen this record first appeared on the registry
Results posted2026-01-06actualWhen the sponsor posted results to the registry
Record updated2026-01-06actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Irritable Bowel Syndrome With Constipation
  • Functional Constipation

Interventions

  • Drug: Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers)
  • Drug: Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)

Primary outcome

what the primary-completion date above is the date OF
Number of Participants With Treatment-Emergent Adverse Events (TEAEs).
measured From first dose of study drug until 30 days following last dose of study drug [up to 24 weeks (FC participants) or 52 weeks (IBS-C participants)].

Posted documents

hosted by the registry — we link, never re-serve
Study Protocolposted 2021-04-30 · 1.7 MB · Prot_000.pdf
Statistical Analysis Planposted 2022-07-19 · 467 KB · SAP_001.pdf

Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed